Guidance for Industry 
 
Tablet Scoring:  
Nomenclature, Labeling, and 
Data for Evaluation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. Department of Health and Human Services 
Food and Drug Administration 
Center for Drug Evaluation and Research (CDER) 
March 2013 
CMC 
   
Guidance for Industry 
 
Tablet Scoring: 
Nomenclature, Labeling, and 
Data for Evaluation 
 
 
 
 
Additional copies are available from: 
Office of Communications 
Division of Drug Information, WO51, Room 2201 
Center for Drug Evaluation and Research 
Food and Drug Administration 
10903 New Hampshire Ave., Silver Spring, MD 20993  
Phone: 301-796-3400; Fax: 301-847-8714 
druginfo@fda.hhs.gov  
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. Department of Health and Human Services 
Food and Drug Administration 
Center for Drug Evaluation and Research (CDER) 
March 2013 
CMC 
  Contains Nonbinding Recommendations 
 
TABLE OF CONTENTS 
 
 
 
I.  INTRODUCTION............................................................................................................. 1 
II.  BACKGROUND ............................................................................................................... 1 
III.  DISCUSSION .................................................................................................................... 2 
A.  Guidelines and Criteria ................................................................................................................. 3 
B.  Nomenclature and Product Labeling ........................................................................................... 5 
 
  Contains Nonbinding Recommendations 
 
1
Guidance for Industry  
Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation 
 
 
This guidance represents the Food and Drug Administrations (FDAs) current thinking on this topic.  It 
does not create or confer any rights for or on any person and does not operate to bind FDA or the public.  
You can use an alternative approach if the approach satisfies the requirements of the applicable statutes 
and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for 
implementing this guidance.  If you cannot identify the appropriate FDA staff, call the appropriate 
number listed on the title page of this guidance.  
 
 
 
I.  INTRODUCTION  
 
This guidance provides recommendations to sponsors of new drug applications (NDAs) and 
abbreviated new drug applications (ANDAs) regarding what criteria should be met when 
evaluating and labeling tablets that have been scored.  (A scoring feature facilitates the practice 
of tablet splitting.2)  Specifically, this guidance recommends: 
 
  Guidelines to follow, data to provide, and criteria to meet and detail in an application to 
support approval of a scored tablet. 
 
  Nomenclature and labeling for approved scored tablets. 
 
This guidance does not address specific finished-product release testing, where additional 
requirements may apply to scored tablets.  This guidance does not describe the medical practice 
conditions under which tablet splitting is considered or recommended. 
 
FDAs guidance documents, including this guidance, do not establish legally enforceable 
responsibilities.  Instead, guidances describe the Agencys current thinking on a topic and should 
be viewed only as recommendations, unless specific regulatory or statutory requirements are 
cited.  The use of the word should in Agency guidances means that something is suggested or 
recommended, but not required.  
 
II.  BACKGROUND 
 
The Agency has previously considered tablet scoring as an issue when determining whether a 
generic drug product is the same as the reference listed drug (RLD).3  One characteristic of a 
                                                 
1 This guidance has been prepared by the Office of Pharmaceutical Science in the Center for Drug Evaluation and 
Research (CDER) at the Food and Drug Administration.  
2 A score is a debossed line that runs across the planar surface of the tablet, while tablet splitting is the practice of 
breaking or cutting a higher-strength tablet into smaller portions. 
3 See the Manual of Policies and Procedures on Scoring Configuration of Generic Drug Products (5223.2), 
November 1, 1995. 
  1  Contains Nonbinding Recommendations 
 
tablet dosage form is that it may be manufactured with a score or scores.  This characteristic is 
useful because the score can be used to facilitate the splitting of the tablet into fractions when 
less than a full tablet is desired for a dose.  Although there are no standards or regulatory 
requirements that specifically address scoring of tablets, the Agency recognizes the need for 
consistent scoring between a generic product and its RLD. 
 
Consistent scoring ensures that the patient is able to adjust the dose, by splitting the tablet, in the 
same manner as the RLD.  This enables the patient to switch between products made by different 
manufacturers without encountering problems related to the dose.  In addition, consistent scoring 
ensures that neither the generic product nor the RLD has an advantage in the marketplace 
because one is scored and one is not.   
 
CDERs Drug Safety Oversight Board considered the practice of tablet splitting at its October 
2009 and November 2010 meetings.4  During those meetings, they discussed how insurance 
companies and doctors are increasingly recommending that patients split tablets, either to adjust 
the patients dose or as a cost-saving measure.  Because of this, the Agency conducted internal 
research on tablet splitting and concluded that in some cases, there are possible safety issues, 
especially when tablets are not scored or evaluated for splitting.  The Agencys concerns with 
splitting a tablet included variations in the tablet content, weight, disintegration, or dissolution, 
which can affect how much drug is present in a split tablet and available for absorption.  In 
addition, there may be stability issues with splitting tablets.5,6  
 
Tablet splitting also is addressed in pharmacopeial standards.  The European Pharmacopeia (EP) 
currently applies accuracy of subdivision standards for scored tabletsand has at various times 
also included standards for content uniformity, weight variation, and loss of masswhile the 
United States Pharmacopeia (USP) published a Stimuli article in 2009 proposing criteria for loss 
of mass and accuracy of subdivision for split tablets.7 
 
III.  DISCUSSION    
 
As an outgrowth of these discussions, we are providing recommendations for application content 
regarding the scientific basis for functional scoring on solid oral dosage form products to ensure 
the quality of both NDA and ANDA scored tablet products.  To accomplish this, we have 
developed consistent and meaningful criteria by which scored tablets can be evaluated and 
labeled by (1) providing a harmonized approach to chemistry, manufacturing, and controls 
(CMC) reviews of scored tablets; (2) ensuring consistency in nomenclature (e.g., score versus 
bisect) and labeling; and (3) providing information through product labeling or other means to 
healthcare providers. 
 
                                                 
4 Public summaries of the Drug Safety Oversight Board meetings are available at 
www.fda.gov/AboutFDA/CentersOffices/CDER/ucm082136.htm.  
5 Na Zhao et al., 30 November 2010, 401(1-2), Tablet Splitting: Product quality assessment of metoprolol succinate 
extended release tablets, International Journal of Pharmaceutics. 
6 Rakhi Shah et. al., 26 August 2010, Tablet Splitting of a Narrow Therapeutic Index Drug: A Case with 
Levothyroxine Sodium, AAPS PharmSciTech. 
7 Geoff Green et al., November-December 2009, 35(6), Pharmacopeial Standards for the Subdivision 
Characteristics of Scored Tablets, Pharmacopeial Forum. 
  2  Contains Nonbinding Recommendations 
 
A.  Guidelines and Criteria 
 
Below are guidelines and criteria by which a scored tablets characteristics will be evaluated as 
part of the review process: 
 
1.  The dosage amount meant to be achieved after splitting the tablet should not be below 
the minimum therapeutic dose indicated on the approved labeling. 
  
2.  The split tablet should be safe to handle and not pose risk of unintended drug 
exposure.  
 
3.  Modified release products for which the control of drug release can be compromised 
by tablet splitting should not have a scoring feature.  
 
4.  The split tablet, when stored in pharmacy dispensing containers (no seal/no 
desiccant), should demonstrate adequate stability for a period of 90 days at 25o C, 
plus or minus 2o C/60 percent Relative Humidity (RH), plus or minus 5 percent RH. 
 
5.  The split tablet portions should meet the same finished-product testing requirements 
as for a whole-tablet product with equivalent strength.  A risk assessment should be 
provided to justify the tests and criteria for product with the proposed functional 
scoring.  The resulting data should be provided to the Agency for evaluation.  The 
assessment should be undertaken on both tablets that are split nonmechanically (by 
hand) and tablets that are split mechanically (with a tablet splitter).  Any 
recommended dissolution test data must be generated on a minimum of 12 individual 
split tablet portions. 
  
Below are the typical criteria, by dosage form, that should be assessed during 
Pharmaceutical Development (3.2.P.2.) of NDAs and ANDAs and during 
primary/exhibit stability batches and scale-up.  As indicated above, a risk assessment 
should be performed to justify criteria for each product. 
 
New products that do not meet the criteria should not have a scoring feature or any 
reference to scoring (including language such as bisected, etc.) in the labeling. 
 
a.  Immediate Release Solid Oral Dosage Forms 
 
  USP General Chapter <905> Uniformity of Dosage Units - Testing for Weight 
Variation is permitted for split tablet portions intended to contain 25 mg or 
more of a drug substance that comprises 25 percent or more (by weight) of the 
split tablet portion.  Otherwise, the test for Content Uniformity should be 
used.8 
 
                                                 
8 For the purpose of this guidance, each split portion of a whole tablet is considered a unit of dose and should meet 
the uniformity of dosage unit requirement. 
  3  Contains Nonbinding Recommendations 
 
  Tablet splitability at both ends of the proposed hardness range should be 
demonstrated by: 
 
1.  Testing 15 tablets to ensure a loss of mass of less than 3.0 percent 
between the individual segments (30 for bisected tablets, 45 for 
trisected tablets, etc.) when compared to the whole tablet.  The 
resulting data for each tablet should be provided to the Agency for 
evaluation. 
 
2.  Confirming that the split tablet portions meet the USP Friability 
requirement.9  
 
  Dissolution data on split tablet portions should meet finished-product release 
requirements.   
 
b.  Modified Release Solid Oral Dosage Forms (Using Matrix Technology) 
 
  All above criteria under section III.A.5.a should be met. 
 
  Dissolution should be demonstrated at both ends of the hardness range. 
 
  Dissolution on whole versus split tablet portions should meet the similarity 
factor (f2) criteria.10 
 
c.   Modified Release Solid Oral Dosage Forms (Using Compressed Film Coated 
Components) 
 
  All above criteria under sections III.A.5.a and III.A.5.b should be met. 
 
  Dissolution profile on pre-compressed beads versus post-compressed whole 
and split tablet portions should meet similarity factor (f2) criteria to ascertain 
the integrity of beads during compression. 
                                                 
9 See USP General Chapter <1216> Tablet Friability. 
10 See the guidance for industry on Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 
1997.  We update guidances periodically.  To make sure you have the most recent version of a guidance, check the 
FDA Drugs guidance page at 
www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. 
 
  4  Contains Nonbinding Recommendations 
 
6.  Scoring configuration of generic drug products should be the same as the RLD.11  
 
  Where the scoring configuration is protected by patent, contact the Office of 
Generic Drugs for guidance. 
  
  For scoring configurations proposed for abbreviated applications that were 
accepted through the suitability petition process, contact the Office of Generic 
Drugs for guidance. 
 
7.  An evaluation of the tablet splitability should be provided during the postapproval 
period for any product changes at Level 2 and Level 3 as defined in the Agencys 
Scale-up and Post-Approval Changes (SUPAC) guidances.12 
 
B.  Nomenclature and Product Labeling 
 
New products that meet the above-referenced criteria can be labeled as having functional 
scoring.  Such labeling should appear in all of the following sections of the prescribing 
information13: 
 
  Dosage Forms and Strength section of the Highlights. 
  Dosage Forms and Strength section of the Full Prescribing Information.  
  How Supplied section of the Full Prescribing Information. 
 
For currently marketed products, manufacturers have the option to perform such an assessment 
and provide data for evaluation to the drug product application.  Product labeling should be 
updated to state that it has functional scoring.  In this way, the use of the term functional scoring 
in the labeling can communicate to healthcare providers that the product has been evaluated 
against the established criteria. 
                                                 
11 See the Manual of Policies and Procedures on Scoring Configuration of Generic Drug Products (5223.2), 
November 1, 1995, for information on what should happen if a change is made to the RLD. 
12 Go to www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064979.htm for a listing 
of all SUPAC guidances. 
13 See 21 CFR 201.57(a)(8) and 201.57(c)(4)(ii). 
  5